Malmö University Publications
Change search
Link to record
Permanent link

Direct link
Riaz, Azra
Publications (3 of 3) Show all publications
Campos Pacheco, J. E., Yalovenko, T., Riaz, A., Kotov, N., Davids, C., Persson, A., . . . Valetti, S. (2024). Inhalable porous particles as dual micro-nano carriers demonstrating efficient lung drug delivery for treatment of tuberculosis. Journal of Controlled Release, 369, 231-250, Article ID S0168-3659(24)00165-2.
Open this publication in new window or tab >>Inhalable porous particles as dual micro-nano carriers demonstrating efficient lung drug delivery for treatment of tuberculosis
Show others...
2024 (English)In: Journal of Controlled Release, ISSN 0168-3659, E-ISSN 1873-4995, Vol. 369, p. 231-250, article id S0168-3659(24)00165-2Article in journal (Refereed) Published
Abstract [en]

Inhalation therapy treating severe infectious disease is among the more complex and emerging topics in controlled drug release. Micron-sized carriers are needed to deposit drugs into the lower airways, while nano-sized carriers are of preference for cell targeting. Here, we present a novel and versatile strategy using micron-sized spherical particles with an excellent aerodynamic profile that dissolve in the lung fluid to ultimately generate nanoparticles enabling to enhance both extra- and intra-cellular drug delivery (i.e., dual micro-nano inhalation strategy). The spherical particles are synthesised through the condensation of nano-sized amorphous silicon dioxide resulting in high surface area, disordered mesoporous silica particles (MSPs) with monodispersed size of 2.43 μm. Clofazimine (CLZ), a drug shown to be effective against multidrug-resistant tuberculosis, was encapsulated in the MSPs obtaining a dry powder formulation with high respirable fraction (F.P.F. <5 μm of 50%) without the need of additional excipients. DSC, XRPD, and Nitrogen adsorption-desorption indicate that the drug was fully amorphous when confined in the nano-sized pores (9-10 nm) of the MSPs (shelf-life of 20 months at 4 °C). Once deposited in the lung, the CLZ-MSPs exhibited a dual action. Firstly, the nanoconfinement within the MSPs enabled a drastic dissolution enhancement of CLZ in simulated lung fluid (i.e., 16-fold higher than the free drug), increasing mycobacterial killing than CLZ alone (p = 0.0262) and reaching concentrations above the minimum bactericidal concentration (MBC) against biofilms of M. tuberculosis (i.e., targeting extracellular bacteria). The released CLZ permeated but was highly retained in a Calu-3 respiratory epithelium model, suggesting a high local drug concentration within the lung tissue minimizing risk for systemic side effects. Secondly, the micron-sized drug carriers spontaneously dissolve in simulated lung fluid into nano-sized drug carriers (shown by Nano-FTIR), delivering high CLZ cargo inside macrophages and drastically decreasing the mycobacterial burden inside macrophages (i.e., targeting intracellular bacteria). Safety studies showed neither measurable toxicity on macrophages nor Calu-3 cells, nor impaired epithelial integrity. The dissolved MSPs also did not show haemolytic effect on human erythrocytes. In a nutshell, this study presents a low-cost, stable and non-invasive dried powder formulation based on a dual micro-nano carrier to efficiently deliver drug to the lungs overcoming technological and practical challenges for global healthcare.

Place, publisher, year, edition, pages
Elsevier, 2024
Keywords
Clofazimine, Disordered mesoporous silica particles, Dissolution enhancement, Dried powder formulation, Dual micro-nano carrier, Lung drug delivery, Soluble carrier
National Category
Pharmaceutical Sciences
Identifiers
urn:nbn:se:mau:diva-66943 (URN)10.1016/j.jconrel.2024.03.013 (DOI)001219489000001 ()38479444 (PubMedID)2-s2.0-85189001903 (Scopus ID)
Available from: 2024-04-26 Created: 2024-04-26 Last updated: 2024-05-23Bibliographically approved
Campos Pacheco, J. E., Riaz, A., Falkman, P., Feiler, A., Ekstrom, M., Pilkington, G. & Valetti, S. (2023). Encapsulation of clofazimine in mesoporous silica as a potential dry powder formulation for treating tuberculosis. Journal of Aerosol Medicine, 36(6), A13-A13, Article ID A13.
Open this publication in new window or tab >>Encapsulation of clofazimine in mesoporous silica as a potential dry powder formulation for treating tuberculosis
Show others...
2023 (English)In: Journal of Aerosol Medicine, ISSN 1941-2711, E-ISSN 1941-2703, Vol. 36, no 6, p. A13-A13, article id A13Article in journal, Meeting abstract (Other academic) Published
National Category
Biomedical Laboratory Science/Technology
Identifiers
urn:nbn:se:mau:diva-66242 (URN)001126390700043 ()
Available from: 2024-03-07 Created: 2024-03-07 Last updated: 2024-03-07Bibliographically approved
Riaz, A., Gidvall, S., Prgomet, Z., Hernandez, A. R., Ruzgas, T., Nilsson, E. J., . . . Valetti, S. (2023). Three-Dimensional Oral Mucosal Equivalents as Models for Transmucosal Drug Permeation Studies. Pharmaceutics, 15(5), 1513-1513
Open this publication in new window or tab >>Three-Dimensional Oral Mucosal Equivalents as Models for Transmucosal Drug Permeation Studies
Show others...
2023 (English)In: Pharmaceutics, ISSN 1999-4923, E-ISSN 1999-4923, Vol. 15, no 5, p. 1513-1513Article in journal (Refereed) Published
Abstract [en]

Oral transmucosal administration, where drugs are absorbed directly through the non-keratinized, lining mucosa of the mouth, represents a solution to drug delivery with several advantages. Oral mucosal equivalents (OME) developed as 3D in vitro models are of great interest since they express the correct cell differentiation and tissue architecture, simulating the in vivo conditions better than monolayer cultures or animal tissues. The aim of this work was to develop OME to be used as a membrane for drug permeation studies. We developed both full-thickness (i.e., connective plus epithelial tissue) and split-thickness (i.e., only epithelial tissue) OME using non-tumor-derived human keratinocytes OKF6 TERT-2 obtained from the floor of the mouth. All the OME developed here presented similar transepithelial electrical resistance (TEER) values, comparable to the commercial EpiOral™. Using eletriptan hydrobromide as a model drug, we found that the full-thickness OME had similar drug flux to EpiOral™ (28.8 vs. 29.6 µg/cm2/h), suggesting that the model had the same permeation barrier properties. Furthermore, full-thickness OME showed an increase in ceramide content together with a decrease in phospholipids in comparison to the monolayer culture, indicating that lipid differentiation occurred due to the tissue-engineering protocols. The split-thickness mucosal model resulted in 4–5 cell layers with basal cells still undergoing mitosis. The optimum period at the air–liquid interface for this model was twenty-one days; after longer times, signs of apoptosis appeared. Following the 3R principles, we found that the addition of Ca2+, retinoic acid, linoleic acid, epidermal growth factor and bovine pituitary extract was important but not sufficient to fully replace the fetal bovine serum. Finally, the OME models presented here offer a longer shelf-life than the pre-existing models, which paves the way for the further investigation of broader pharmaceutical applications (i.e., long-term drug exposure, effect on the keratinocytes’ differentiation and inflammatory conditions, etc.).

Place, publisher, year, edition, pages
MDPI, 2023
Keywords
oral transmucosal delivery, oral mucosal equivalents, drug permeation, 3R principles, 3D in vitro models
National Category
Pharmaceutical Sciences
Identifiers
urn:nbn:se:mau:diva-61046 (URN)10.3390/pharmaceutics15051513 (DOI)000997495400001 ()37242755 (PubMedID)2-s2.0-85160448981 (Scopus ID)
Funder
The Crafoord Foundation, 20210937Knowledge Foundation, 20190010
Available from: 2023-06-19 Created: 2023-06-19 Last updated: 2023-08-15Bibliographically approved
Organisations

Search in DiVA

Show all publications